Obesity
📧 Sign up to get email alerts when something new happens for Obesity.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2009-07-20Clinical Trial Update: Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS) [Phase 3]
Phase 3 VENUS trial of rimonabant in Japanese obese patients with dyslipidemia has been terminated.
-
EMA withdrawal · 2009-01-30EMA Withdrawn: Zimulti (rimonabant) — sanofi-aventis
The EMA has withdrawn Zimulti (rimonabant) from the market, with obesity as the therapeutic area and Sanofi-Aventis as the marketing authori…
-
EMA withdrawal · 2009-01-30EMA Withdrawn: Acomplia (rimonabant) — sanofi-aventis
Acomplia (rimonabant) has been withdrawn from the market by Sanofi-Aventis; status indicates withdrawal for obesity indications.
-
CLINICAL_TRIALS withdrawal · 2008-01-09Clinical Trial Update: BMS-646256 in Obese and Overweight Type 2 Diabetics [Phase 2, Phase 3]
A Phase 2/Phase 3 trial of BMS-646256 in obese and overweight adults with Type 2 diabetes was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2007-08-21Clinical Trial Update: Inflammatory Response and Pregnancy Outcome in Women With Type 2 Diabetes or Overweight [Phase 1]
A Phase 1 trial investigating inflammatory response and pregnancy outcomes in women with type 2 diabetes mellitus or overweight has been wit…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.